HbA1c screening in patients with early breast cancer receiving endocrine therapy.

ABSTRACT:

Objective

Type 2 diabetes increases the risk of developing breast cancer, while endocrine therapy for early breast cancer may elevate the risk of type 2 diabetes. Studies suggest screening patients with early breast cancer receiving endocrine therapy for type 2 diabetes, but the optimal strategies remain unclear. We assessed haemoglobin A1c (HbA1c) screening adherence, the prevalence of HbA1c levels above the normal range (≥ 42 mmol/mol), and an HbA1c follow-up procedure.

Methods

Patients with early (stage I-III) breast cancer without diabetes receiving endocrine therapy were offered a single HbA1c screening test after treatment initiation at Aarhus University Hospital, Denmark, from October 2022 to April 2023. HbA1c ≥ 42 mmol/mol was classified as prediabetic (42-47 mmol/mo

SUBMITTER: Nissen L 

PROVIDER: S-EPMC12606721 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature